Cocrystal Pharma, Inc., a biotechnology company developing novel antiviral therapeutics, announced a $5M investment from OPKO Health, Inc., a longtime investor in the company, has increased its position through this investment as the company advances its lead norovirus program toward Phase 1b topline data later this year.
Cocrystal Pharma Announces $5M Private Placement with OPKO Health
Share: